Relationship between the grade of radiation pneumonitis (RP) and treatment outcome in lung cancer patients has not been clarified yet. The purpose of this study was to retrospectively evaluate the relationship in patients with primary lung cancer treated by radiotherapy. One hundred thirty-five patients who underwent definitive radiotherapy with known grade of RP were analyzed. RP was scored by using the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria. Survival and local control data were analyzed in relation to the grade of RP. RP was grade 0 in 5 patients, grade 1 in 71, grade 2 in 39, grade 3 in 15 (11%), grade 4 in 0 and grade 5 in 5 (3.7%). There were no significant correlations between patient or tumor characteristics and grade of RP. Excluding 5 patients with grade 5 pneumonitis, survival rates were similar between those with grade 0 or 1 pneumonitis and those with grade 2 or 3. Also, there was no difference in survival between patients with grade 0-2 pneumonitis and those with grade 3. Local control rates were similar between the two groups. Grade of RP did not appear to be associated with prognosis when patients with grade 5 pneumonitis were excluded from analysis.
INTRODUCTION
Radiotherapy is the mainstay of treatment in patients with nonsmall cell lung cancer (NSCLC) with locally advanced disease or poor pulmonary function [1] [2] [3] [4] [5] [6] [7] [8] . It is well documented that conventionally fractionated radiotherapy for NSCLC to a total dose of 50-60 Gy or more improves locoregional control and survival rate [9] . In addition, recent studies have shown excellent results for stage I lung cancer treated with stereotactic radiotherapy [10] [11] [12] .
On the other hand, pulmonary toxicity such as radiation pneumonitis (RP) and pulmonary fibrosis commonly develops after radiation therapy. The grade of pulmonary toxicity varies in individual patients so that it may influence the prognosis of patients; severe RP was reported to be an adverse prognostic factor in patients with primary lung cancer [13] . Recently, several studies have shown that inflammatory cytokines and cell adhesion molecules play an important role in radiation-induced pulmonary injury [14] . Plasma transforming growth factor-β levels have been reported to be associated with occurrence of RP [14] [15] [16] . Also, RP is reported to be associated with levels of some interleukins and tumor necrosis factors [17, 18] , which have anti-tumor effects [19, 20] . In our experiences, a number of patients with residual mass after radiotherapy developed severe RP, and the residual mass was cov-ered by dense fibrosis. Thereafter, they experienced no local recurrence. Therefore, we hypothesized that severe RP may contribute to local control by developing severe inflammation around the residual tumor mass in some patients.
In this study, therefore, we attempted to investigate relationship between the grade of RP and prognosis and local control of NSCLC patients who were treated by definitive conventional radiotherapy and were followed at our hospitals; stages and RP grades could be evaluated from both clinical and radiological findings in all of these patients.
MATERIALS AND METHODS

Patients and treatment characteristics
The subjects of this study were 135 patients with histologically-confirmed NSCLC who had been appropriately staged and treated between March 1990 and August 2005, and followed until death or for at least 6 months at our hospitals. There were 112 men and 23 women. The median age of the patients was 69 years (range, 46-87 years). Patients were staged according to the 1997 International Union Against Cancer (UICC) classification system; patients seen before 1997 were restaged according to the system.
No patient underwent surgical resection. All patients were treated using 4, 6 or 10 MV photons from linear accelerators. The patients were generally treated with 1.8-2.0 Gy daily fractions using parallel opposed anteroposterior fields to 40-45 Gy, followed by offcord oblique fields to 58-75.2 Gy (median, 66 Gy). Patients receiving a total dose of 57 Gy or less were excluded. Sixty-five patients received variable systemic platinum-based chemotherapy.
Evaluation of RP
RP was scored according to the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) acute radiation morbidity scoring criteria (Table 1 ) [21] .
Statistical analysis
Differences in distribution of patient, tumor and treatment characteristics and rates of local relapse between lower-grade RP and higher-grade RP groups were examined by the Mantel-Haenszel χ 2 test. Overall survival rates of the patients were calculated from the date of starting radiotherapy using the Kaplan-Meier method, and differences between the curves were examined by the log-rank test. Differences were considered significant when a P value was <0.05. Multivariate analysis of potential prognostic factors was carried out using the Cox proportional hazards model. All analyses were performed using a computer software StatView version 5 (SAS Institute Inc., Cary, NC, USA).
RESULTS
There were 99 deaths during follow-up. Causes of death were cancer in 72 patients, RP-related in 5, and other in 4 patients (traffic accident, emphysema, bacterial pneumonia, and suicide in 1 patient each). The cause of death was unknown in the remaining 18 patients. For all 135 patients, median survival time (MST) was 15 months and overall survival rates were 62%, 21%, and 15% at 1, 3, and 5 years, respectively. The 5-year overall survival rate was 13% for stage I patients, 23% for stage II, 14% for stage IIIA and 10% for stage IIIB.
Of the 135 patients, RP was grade 0 in 5 (3.7%), grade 1 in 71 (53%), grade 2 in 39 (29%), grade 3 in 15 (11%), grade 4 in none (0%) and grade 5 in 5 (3.7%). Relationship between RP grades and patient and tumor characteristics including age, gender, World Health Organization performance status (PS), clinical stage, primary tumor location (upper lobe vs. middle or lower lobe) and tumor histology, total radiation dose, use of chemotherapy, and local control are shown in Tables 2 and 3 . There were no differences in any of these characteristics when lower-grade RP groups (grade 0, 1 or 0-2) were compared with higher-grade RP groups (grade 2-5 or 3-5). Also, these tables showed that there were no unbalances in distribution of these 58 Figure 1 shows survival curves for the 130 patients, excluding 5 patients with grade 5 RP, according to the grade of RP (grade 0 or 1 vs. grade 2 or 3). There was no difference in prognosis of the patients. Figure 2 shows survival curves for patients with grade 0-2 RP and those with grade 3 RP; again, there was no difference in prognosis of the patients (P=0.10). Figure 3 shows survival curves for stage III patients with grade 0-2 RP and those with grade 3 RP, and there was no difference in prognosis of the patients (P=0.33). Table 4 summarizes MST and 3-year survival rate (3-YSR) according to 9 potential prognostic factors (age, gender, PS, stage, tumor location, histology, total radiation dose, use of chemotherapy, and RP grade), excluding 5 patients with grade 5 RP. Patients with upper lobe tumors had better survival than those with middle or lower lobe tumors, and stage I or II patients tended to do better than stage III patients (P=0.060).
Patients receiving higher doses (above median: >66 Gy) had better survival than those receiving lower doses. Multivariate analysis was carried out for 4 factors with P < _ 0.1 (stage, tumor location, radiation dose and RP grade); clinical stage and radiation dose were found to have significant influences on patient survival, whereas tumor location and RP grade were not. Figure 4 shows overall survival curves according to the total radiation dose, including 5 patients with grade 5 RP. In this analysis too, patients receiving higher doses did better than those receiving lower doses.
Local control status was known in 110 patients excluding 5 patients with grade 5 RP. We could not determine the exact date of local recurrence in many patients, so Kaplan-Meier analysis was not possible. Local relapse was observed in 34 of 67 patients (51%) with grade 0 or 1 RP, while it was seen in 20 of 43 patients (47%) with grade 2 or 3 RP (P=0.61). Also, local relapse was seen in 52 of 101 patients (51%) with grade 0-2 RP and in only 2 of 9 patients (22%) with grade 3 RP; the difference was, however, not sig- Five patients with grade 5 RP had received radiation doses of 60, 60, 66, 70, and 72 Gy, respectively. Their survival time was only 2, 2, 3.5, 4, and 2.5 months, respectively. Although no local tumor regrowth was noted in any of the patients at the time of their death, observation period was considered to be too short to evaluate local control in these patients.
DISCUSSION
We analyzed treatment outcome in 135 patients with stage I-III NSCLC treated by definitive radiotherapy. The 5-year overall survival rate was 15%, which is not better than previously reported results [3] [4] [5] . This may not be surprising because 80% of the patients had stage III disease. The overall survival rates for stage I patients (13% at 5 years) were apparently low as compared with the recently reported results of stereotactic radiotherapy [10] [11] [12] . This low survival rate was partly due to a relatively large number of intercurrent death in stage I patients, seen in 8 of 13 patients. Nevertheless, it seems clear that the results of stereotactic irradiation for stage I patients are far better than those for conventional radiotherapy.
RP is one of the most common and important complications in patients with lung cancer who undergo radiation therapy to the thorax. The incidence of severe RP ranges from approximately 5% to 15% with radiotherapy or chemoradiotherapy [22] [23] [24] . In the present study, 15% of the patients had grade 3 or higher RP, and 5 (3.7%) died of severe RP. The incidence of grade 3-5 RP in the present study is not remarkably different from those reported previously, although the incidence of grade 5 RP appears slightly higher [13, 25] .
In several studies, age, gender, PS, clinical stage, primary tumor location (upper lobe vs. middle or lower lobe), tumor histology, and use of chemotherapy have been reported to be associated with the incidence of severe RP [26] [27] [28] [29] . However, no significant relationship was observed in the present study between the grade of RP and patient, tumor or treatment characteristics. Analysis of larger numbers of patients may prove subtle differences regarding association of these factors with the severity of RP. Radiation field size could not be evaluated, but RP grade distribution was not correlated with tumor stage.
We found no significant difference in survival between patients with grade 0 or 1 RP and those with grade 2 or 3 RP. Also, no significant difference was found between patients with grade 0-2 RP and those with grade 3 RP. This was also true when only stage III patients were analyzed. These results are in contrast to those reported by Inoue et al. [13] who showed that severe RP (RTOG grade 3 or 4) was associated with worse prognosis. In our experiences, severe RP, whenever it recovers, does not seem to adversely affect the patient prognosis. However, our hypothesis that severe but recoverable RP might contribute to improved prognosis was not supported. On the other hand, only 2 of 9 patients with grade 3 RP developed local recurrence. In future, further analysis with respect to local tumor control with larger numbers of patients, preferably in a prospective fashion, may more clearly answer our question.
If high-grade inflammation associated with severe RP does not contribute to improved tumor control, strategies to prevent RP should be of clinical importance. Recently, it has been shown that protective effect of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II (AII) type 1 receptor blocker from RP is a topic of considerable interest [14, 23] . Several groups reported that ACE inhibitors especially captopril and AII type 1 receptor blocker were effective in protecting lungs from RP and the development of lung fibrosis in rat radiation injury [30] [31] [32] . The possibility remains that administration of ACE inhibitors and AII type 1 receptor blocker might have two beneficial effects: control of radiation-induced side effects and control of hypertension in the future.
CONCLUSION
High-grade RP did not appear to affect prognosis of patients with NSCLC undergoing definitive radiotherapy. However, further prospective studies with larger number of patients appear to be warranted to draw a definite conclusion.
